Ontario’s COVID-19 Genomics Rapid Response Coalition
About
To accelerate the genomic characterization and surveillance of SARS-CoV-2 in Ontario and to help expedite patient genome sequencing through a coordinated approach bringing together all of the province’s genomics resources and capacity to enable timely and comprehensive genomic analysis.
Genomics
Infrastructure
Standardized Sequencing Methodologies
Bioinformatics
Infrastructure
Data Management & Sharing
The ON-CoV Coalition is designed to provide for method standardization and coordination of:
1
Collecting Patient Samples and Metadata
2
Sequencing
3
Data Curation and Management
4
Epidemiological Studies
This work will expedite real-time testing and reporting to inform public health and public policy, help manage and overcome the ongoing COVID-19 crisis and ensure scalability for Ontario’s future pandemics preparedness.
Why Genomics?
Genomic technologies are the foundation for the solutions necessary to combat the ongoing COVID-19
pandemic. Ontario’s world-leading expertise in genomics, bioinformatics, genomics epidemiology, and artificial intelligence, can expedite Ontario’s response to COVID-19.
The results reported by the Coalition will inform vaccine and therapeutic development.
Why Ontario Genomics?
Over the past 20 years, Ontario Genomics, together with the Ontario Government, Genome Canada, and academic, clinical and industry partners, has built a world-leading genomics ecosystem in Ontario with over $2.7B in funding leveraged for research, translation and the establishment of genomic technology platforms.
Ontario Genomics is well-positioned to provide and promote:
COLLABORATION
LEADERSHIP
EXPERTISE
Members
ONCoV Genomics Coalition Steering Committee
-
Dr. Samira Mubareka, Sunnybrook Health Sciences/University of Toronto
-
Dr. Herveen Sachdeva, Toronto Public Health
-
Dr. Sarah Wootton, University of Guelph
ONCoV Genomics Coalition Members
Aaron Campigotto
University of Toronto
Bettina Hamelin
Ontario Genomics
Samira Mubareka
Sunnybrook Health Sciences / University of Toronto
Danielle Brabant-Kirwan
Health Sciences North
Robyn Lee
Dalla Lana School of Public Health, University of Toronto
Letitia Nadalin Penno
Canadore College
Nahuel Fittipaldi
Public Health Ontario
Andrew G. McArthur
McMaster University
Marc Fiume
DNAstack
Allison McGeer
Sinai Health Systems
Prameet M. Sheth
Kingston Health Sciences Centre / Queen’s University
Jared Simpson
Ontario Institute for Cancer Research
Michael Szego
Unity Health Toronto / University of Toronto
David Villeneuve
Canadore College
Bo Wang
Peter Munk Cardiac Centre, UHN / University of Toronto
Sarah Wootton
University of Guelph
We are proactively working with the research community, partner genome centres, and governments to accelerate the genomic characterization and surveillance of SARS-CoV-2 in Ontario. Learn more and stay up-to-date about our COVID-19 programs and important resources.
Partners
Canada’s BioRevolution 2020 Webinar Series – “Editing our Economic Future: The Power of CRISPR”
September 28, 2000 - 12pm
“Editing our Economic Future: The Power of CRISPR” will showcase a conversation between Gairdner Foundation laureates and leading Canadian researchers on using the opportunities and applications of gene editing, specifically by using CRISPR/Cas9, to transform multiple sectors.
September 15, 2020
Government of Canada: Policy Statement on Research Security and COVID-19
September 14, 2020
The Government of Canada is encouraging all members of the research ecosystem to be aware of the potential risks to their work and asking them to take appropriate measures to protect their knowledge creation and innovations, all while maintaining a strong commitment to Open Science and support for a global research response to the COVID-19 pandemic.
Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus
Key members of the ONCoV Genomics Coalition, Samira Mubareka and Andrew McArthur conducted a collaborative study analyzing and predicting the recombination potential of SARS-CoV-2 and the Middle East respiratory syndrome coronavirus.
September 9, 2020